247048-22-2

Basic information

• Product Name: 1,3,5-benzene triscarboxylic acid tris(pentafluorophenyl) ester
• Synonyms: 1,3,5-benzene triscarboxylic acid tris(pentafluorophenyl) ester
• CAS NO: 247048-22-2
• Molecular Weight: 708.293
• Mol File: 247048-22-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,3,5-benzene triscarboxylic acid tris(pentafluorophenyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-benzene triscarboxylic acid tris(pentafluorophenyl) ester(247048-22-2)
• EPA Substance Registry System: 1,3,5-benzene triscarboxylic acid tris(pentafluorophenyl) ester(247048-22-2)

Safety Data

• Hazardous Substances Data: 247048-22-2(Hazardous Substances Data)

Upstream product

• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 4422-95-1 1,3,5-benzene tris(carbonyl chloride) 
• 554-95-0 benzene-1,3,5-tricarboxylic acid 

Downstream Products

• 847375-84-2 1-(tris{[2-(tert-butoxycarbonyl)ethoxy]methyl}methylaminocarbonyl)benzene-3,5-dicarboxylic acid bis(pentafluorophenyl) ester 

Relevant articles and documents

The effect of monosaccharides on self-assembly of benzenetricarboxamides

The interaction between monosaccharides exhibits an important role in the assembly of monosaccharide-containing molecules. In this work, three common monosaccharides, glucose, galactose and mannose, are employed to investigate the effect of monosaccharide on the self-assembly of benzenetricarboxamide (BTA) core-containing molecules. In the presence of monosaccharides, three benzenetricarboxamide derivatives aggregate into different ordered structures. When alanine linkers are introduced to these molecules between the core and the monosacchride, morphologies of three types of monosaccharide BTAs turned to disordered, meanwhile their structures become similar with the increase of the length of alanine linkers, indicating the disappearance of the monosaccharide effects.

Novel diagnosis and treatment type nano-drug based on molecular shuttle

The invention belongs to the technical field of biology, and relates to a novel diagnosis and treatment type nano-drug based on a molecular shuttle. According to the invention, a drug is linked to twoends of a molecular shuttle guest molecule through a click chemical reaction; by utilizing a drug molecule size effect, the molecular shuttle guest is difficultly be identified and penetrated by a molecular shuttle host; and in a tumor reducing microenvironment, the drug is released while the molecular shuttle guest is liberated, so that the molecular shuttle guest can be quickly, precisely and specifically recognized and penetrated by the molecular shuttle host to form a fusiform near-infrared supramolecular probe, wherein the fusiform near-infrared supramolecular probe can be used for real-timely characterizing the release behavior of the drug at an in-vitro cell level or an in-vivo animal level.

Design and synthesis of inhibitory analogues of LH-RH with increased antiovulatory potency

-